menu
    • menu

    Company profile for Spinogenix

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    In most neurodegenerative diseases we lose connections - synapses – between neurons, a process that contributes to declines in cognition and motor function that characterize these diseases. At Spinogenix we are developing first-in-class, novel small molecule drugs (SPGs) that restore synapses to improve and potentially restore cognitive and motor function. Our approach is unique for diseases of the central nervous system. S...
    In most neurodegenerative diseases we lose connections - synapses – between neurons, a process that contributes to declines in cognition and motor function that characterize these diseases. At Spinogenix we are developing first-in-class, novel small molecule drugs (SPGs) that restore synapses to improve and potentially restore cognitive and motor function. Our approach is unique for diseases of the central nervous system. Spinogenix is developing a new class of therapeutics to restore memory and motor functions lost in neurodegenerative and psychiatric diseases.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    SpinogenixUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    10210 Campus Point Dr, San Diego, California 9212
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://spinogenix.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/spinogenix/about/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Spinogenix Announces WHO Approval of 'tazbentetol'
    Spinogenix Announces WHO Approval of 'tazbentetol'

    01 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/spinogenix-announces-world-health-organization-approval-of-tazbentetol-as-international-non-proprietary-name-for-spg302-302628935.html

    PR NEWSWIRE
    01 Dec 2025
    Share Share
    Spinogenix Unveils Phase 2A Results For SPG302, In ALS
    Spinogenix Unveils Phase 2A Results For SPG302, In ALS

    04 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/spinogenix-presents-topline-phase-2a-clinical-trial-results-for-spg302-a-first-in-class-als-treatment-302603975.html

    PR NEWSWIRE
    04 Nov 2025
    Share Share
    Spinogenix To Unveil SPG601, Phase 2A Trial Results For Fragile X
    Spinogenix To Unveil SPG601, Phase 2A Trial Results For Fragile X

    23 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/spinogenix-to-present-complete-phase-2a-clinical-trial-results-for-spg601-a-first-in-class-fragile-x-syndrome-treatment-at-aacap-conference-302591334.html

    PR NEWSWIRE
    23 Oct 2025
    Share Share
    Spinogenix Reveals Spg302's Neuroprotective Effects In Glaucoma
    Spinogenix Reveals Spg302's Neuroprotective Effects In Glaucoma

    16 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/spinogenix-announces-publication-of-preclinical-study-demonstrating-neuroprotective-effects-of-spg302-in-a-model-of-glaucoma-302586055.html

    PR NEWSWIRE
    16 Oct 2025
    Share Share
    Spinogenix Holds Successful FDA Type C Meeting for SPG601
    Spinogenix Holds Successful FDA Type C Meeting for SPG601

    02 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/spinogenix-announces-positive-type-c-meeting-with-the-fda-for-spg601-in-patients-with-fragile-x-syndrome-fxs-302543653.html

    PR NEWSWIRE
    02 Sep 2025
    Share Share
    Spinogenix Reports Strong Ph 2a Results for SPG302 for Alzheimer
    Spinogenix Reports Strong Ph 2a Results for SPG302 for Alzheimer

    08 Aug 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/spinogenix-announces-positive-first-cohort-results-from-phase-2a-trial-evaluating-spg302-for-alzheimers-disease-302524227.html

    PR NEWSWIRE
    08 Aug 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search